Summit Therapeutics   Report issue

For profit Phase 2 Phase 3
Founded: Abingdon United Kingdom (2003)

Organization Overview

First Clinical Trial
2013
NCT02056808
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Summit (Oxford) Limited | Summit Therapeutics

Active Ingredients

Drugs in Phase 3 Trials (4)

ak112 (2 trials)

pembrolizumab (keytruda) (1 trial)

ridinilazole (5 trials)

vancomycin (Vancocin) (4 trials)

Drugs in Phase 2 Trials (2)

ezutromid (3 trials)

fidaxomicin (dificid) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Clostridium Infections (Phase 3)

Communicable Diseases (Phase 3)

Diarrhea (Phase 2)

Infections (Phase 3)

Muscular Dystrophies (Phase 2)

Muscular Dystrophy, Duchenne (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 10
  • # of Trial APIs: 6